Five Prime Therapeutics Inc (FPRX) 24.07 $FPRX Five

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 10:33 PM

Five Prime Therapeutics Inc (FPRX) 24.07 $FPRX

Five Prime Therapeutics to Host Research & Development Day on May 5, 2015
GlobeNewswire - Wed Apr 22, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company will hold its first Research & Development Day event for the institutional investment community in New York City on May 5, 2015. The formal program and webcast will begin at 8:30 am ET and will conclude at approximately 11:45 am ET.
FPRX: 24.07 (-0.85)

Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?
George Budwell, The Motley Fool - Motley Fool - Wed Apr 22, 7:11AM CDT
Biotechnology is rapidly giving rise to ground-breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand in hand...
AGEN: 6.08 (+0.21), ADXS: 22.18 (+0.10), PFE: 34.93 (+0.04), MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)

Nasdaq stocks posting largest percentage increases
AP - Fri Apr 17, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
FATE: 6.29 (-0.10), MAT: 28.36 (+1.14), CHKE: 22.82 (-0.17), TGLS: 11.98 (+0.70), FPRX: 24.07 (-0.85)

After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 4:38PM CDT

VSTM: 9.99 (unch), NBL: 51.18 (+0.05), SIGM: 8.36 (+0.29), ARGS: 8.48 (-0.11), IBN: 10.30 (+0.12), ERI: 7.50 (+0.30), SGMS: 12.48 (+0.25), BNDX: 53.90 (-0.10), BIND: 7.01 (-0.30), FPRX: 24.07 (-0.85)

Cancer PD-1 inhibitor market only half as large as consensus says analyst
Seeking Alpha - at Seeking Alpha - Tue Mar 31, 11:37AM CDT

MDVN: 128.88 (+0.29), AZN: 73.35 (+0.65), MRK: 57.69 (+0.03), BMY: 66.60 (-0.21), SRNE: 10.36 (-0.43), CELG: 115.54 (+0.72), FPRX: 24.07 (-0.85)

'Mad Money' Lightning Round: Buy, Buy, Buy ConocoPhillips
at The Street - Thu Mar 26, 5:00AM CDT
Cramer likes Ryanair, Pfizer and MeadWestvaco but is avoiding Rovi Corporation, Five Prime Therapeutics and Avon Products.
RYAAY: 66.62 (-0.12), AVP: 8.81 (-0.07), ISIS: 66.26 (-0.03), MWV: 47.23 (+0.53), PFE: 34.93 (+0.04), IP: 53.04 (+0.52), COP: 67.88 (-0.14), VG: 4.91 (-0.05), URI: 95.79 (-2.11), ROVI: 19.46 (+0.10), FPRX: 24.07 (-0.85)

Pfizer Is An Outright Buy - Cramer's Lightning Round (3/25/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Thu Mar 26, 3:55AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 25. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "My take is this: It is going to go even lower because it's part of the highest...
AVP: 8.81 (-0.07), PFE: 34.93 (+0.04), IP: 53.04 (+0.52), COP: 67.88 (-0.14), PCLN: 1,212.90 (+18.64), VG: 4.91 (-0.05), NFLX: 557.68 (-2.76), RYAAY: 66.62 (-0.12), ISIS: 66.26 (-0.03), MWV: 47.23 (+0.53), FPRX: 24.07 (-0.85), ROVI: 19.46 (+0.10), URI: 95.79 (-2.11)

Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
72.52 (+0.43), UTX: 116.96 (+0.01), KRFT: 88.25 (-0.22), PAH: 27.81 (+0.19), INTC: 32.70 (+0.27), PVH: 103.33 (-0.39), VG: 4.91 (-0.05), DFS: 57.89 (-1.37), RYAAY: 66.62 (-0.12), PAYX: 49.28 (+0.22), SONC: 30.75 (+0.14), MWV: 47.23 (+0.53), COST: 146.98 (-0.36), ABBV: 64.52 (+0.91), MMP: 81.26 (+0.05), REGN: 472.63 (+9.41), CSCO: 28.62 (-0.07), URI: 95.79 (-2.11), ROVI: 19.46 (+0.10), AVP: 8.81 (-0.07), KR: 70.39 (-1.44), FB: 84.63 (+1.01), IP: 53.04 (+0.52), PFE: 34.93 (+0.04), DIS: 107.94 (+0.26), COP: 67.88 (-0.14), AMGN: 169.10 (+0.64), WFC: 54.67 (+0.39), DENN: 11.51 (-0.06), CELG: 115.54 (+0.72), WWAV: 45.54 (-0.56), ISIS: 66.26 (-0.03), FPRX: 24.07 (-0.85)

Weakness Seen in Five Prime Therapeutics (FPRX) Estimates: Should You Stay Away? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:43AM CDT
Five Prime Therapeutics has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
ACOR: 33.34 (-1.33), FPRX: 24.07 (-0.85)

Vaccinex Signs Multi-Target Antibody Discovery Deal With Five Prime Therapeutics
GlobeNewswire - Thu Mar 19, 12:30PM CDT
Vaccinex, Inc. announced today that the company has entered into a multi-target collaboration agreement with Five Prime Therapeutics, Inc. to utilize Vaccinex's ActivMAb(R) antibody discovery platform for the discovery of monoclonal antibodies against novel targets identified by Five Prime's proprietary discovery platform.
FPRX: 24.07 (-0.85)

Five Prime ups revenues 39% in FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 8:08AM CDT

FPRX: 24.07 (-0.85)

Five Prime Therapeutics' (FPRX) CEO Rusty Williams on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 9:25PM CDT

FPRX: 24.07 (-0.85)

Five Prime Therapeutics posts 4Q loss
Automated Insights - Tue Mar 17, 3:46PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Five Prime Therapeutics Inc. (FPRX) on Tuesday reported a loss of $11.8 million in its fourth quarter.
FPRX: 24.07 (-0.85)

Five Prime Therapeutics misses by $0.45, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:07PM CDT

FPRX: 24.07 (-0.85)

Five Prime Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 17, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2014.
BMY: 66.60 (-0.21), FPRX: 24.07 (-0.85)

Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on March 17
GlobeNewswire - Tue Mar 10, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2014 financial results on Tuesday, March 17, 2015, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, March 17, 2015 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 24.07 (-0.85)

Five Prime Therapeutics to Present at the RBC Capital Markets 2015 Healthcare Conference
GlobeNewswire - Wed Feb 18, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25, 2015 at 10:30 AM Eastern Standard Time. The conference will take place at the New York Palace Hotel in New York City.
FPRX: 24.07 (-0.85)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Viking Ventures: Impacts of VK2735 on Obesity Examined

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...